News and Announcements
Bioactive Laboratories Pty Ltd – CEO Interview
- Published June 25, 2014 3:34PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Bioactive Laboratories specialises in plant based solutions for human health.
They have developed the first anti-inflammatory and pain relieving agent that is gentle to the stomach. Studies show it rivals the drug efficacy and strength of NSAIDs such as Voltaren, without digestive side effects.
Global market sectors worth an estimated $560Billion annually make anti-inflammatories & pain agents the most widely used of all drugs and complementary medicines.
A faster route to market exists, than traditional biotech via the booming Complementary Medicine market to supply bulk powders & extracts.
Profitability within four years is predicted via a conservative financial model. This hybrid complementary medicine/drug development business model, suggests self funding for the development pipeline that includes drug candidates & revolutionary plant based solutions for type-2 diabetes.
Customers such as pharmaceutical & complementary medicine companies have been approached and are anxious to gain access.
To hear the latest on Bioactive Laboratories straight from the source, please listen to Rick Ferdinands, Founder & MD.
Executive Interviews
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
